Oncology | Absolute Q

Pushing the limit of cancer detection


Applications for digital PCR in oncology are myriad, from biomarker discovery to early detection, liquid biopsy research as well as monitoring recurrence and response to treatment. For all applications in translational cancer research, Absolute Q brings 4-color multiplexing capabilities, improved sensitivity, and a one-step, walkaway workflow to your application.

Digital PCR in Oncology Applications Webinar

AACR 2020 Posters

Screen Shot 2020-06-23 at 11.27.04 AM

Fully Integrated Single Instrument Imaging-based Digital PCR Platform

Download Application note

LMNX AACR 2020 Poster

Discriminatory 11-Plex Assay Designed to Monitor Estrogen Receptor Mutations Using a Novel, Melt-Analysis Capable Digital PCR Platform

Download Application note

Rare target quantification in liquid biopsy

Identifying oncogenic mutations via liquid biopsy can be used for early detection, surveillance, measure therapeutic response, residual disease, and emerging resistance to targeted therapies. Here, we demonstrate robust detection of 5 different hotspot mutations down to 0.1% allelic frequency. See the TaqMan™ protocol here.

Download Tech note
Download Application note

Absolute quantitation of ultra-rare transcripts in blood cancers

The oncogenic BCR-ABL1 gene fusion is found in 95% of chronic myeloid leukemia cases, and is used as a biomarker to measure response to treatment as well as disease recurrence. These molecules are often very rare in the blood, but here we demonstrate detection of ultra-rare molecule detection down to 0.01 percent of the BCR-ABL1 fusion transcript.

Sensitive and precise detection of treatment-relevant cancer mutations with an existing 2-enzyme PCR chemistry

Tyrosine kinase inhibitors are a cornerstone of precision medicine and are a standard of care for those harboring oncogenic mutations. Unfortunately, drug-resistant mutations are a common result of this treatment. Sensitive and precise detection of these variants are critical to make well-informed treatment decisions. See how the Absolute Q was used alongside an existing two-enzyme PCR chemistry to enable highly precise interrogation of challenging genomic regions, identifying EGFR pT790M mutations down to 5 copies per reaction – all without the need for a standard curve.
Download Application note

Speak with an Application Scientist